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etter to the Editor
NCA-negative  idiopathic  pulmonary  ﬁbrosis  developed
nto ANCA-positive  rapidly  progressive  glomerulonephritis
fter 12 years  follow  up
ibrosis  pulmonar  idiopática  ANCA  negativa  desarrollada  en  la
lomerulonefritis  de  evolución  rápida  en  ANCA  positiva  después  de
2  an˜os  de  seguimiento
ear Editor,
diopathic pulmonary ﬁbrosis (IPF) is a chronic, progressive
brotic disorder of the lung parenchyma. Rapidly progres-
ive glomerulonephritis (RPGN) is a disease characterized by
cute loss of renal function with glomerulonephritis, which
s diagnosed by a pathologic pattern of crescent formation. A
ubgroup of RPGN is associated with anti-neutrophil cytoplas-
ic  antibodies (ANCA). ANCA are abnormal auto-antibodies
hich are particularly related to small-vessel vasculitis in the
idneys. The perinuclear (p-ANCA) and cytoplasmic (c-ANCA)
mmunoﬂuorescent patterns mainly correspond to antibo-
ies directed against myeloperoxidase (MPO) and proteinase-
 (PR3), respectively. Herein, we report a case of a 37-year-old
an  with a history of ANCA (−) IPF who abruptly developed
NCA (+) RPGN with pulmonary renal syndrome after 12.5
ears.
A 37-year-old man  had a history of ANCA (−) IPF and
outy arthritis under control with prednisolone 5 mg  QOD
nd colchicines 0.5 mg  QD for over 12.5 years. A month prior
o presentation, he began to experience intermittent mus-
le aches, arthralgias over bilateral hands and foamy urine.
e ﬁnally presented to the emergency department with com-
laints of progressive shortness of breath, hemoptysis, poor
rine output, and bilateral lower leg edema for one week. The
hysical examination was notable for respiratory discomfort,
ilateral rales and grade 1 pitting edema of bilateral
ower limbs. No petechiae, ecchymosis or costovertebral
ngle tenderness were noted. Blood tests showed leuko-
ytosis, azotemia (BUN: 159 mg/dL, creatinine: 21.1 mg/dL),
yperkalemia, and anion gap metabolic acidosis. Urinaly-
is revealed proteinuria and hematuria. Immunologic studiesPlease cite this article in press as: Yeung C-Y, et al. ANCA-negative idiopath
sive glomerulonephritis after 12 years follow up. Nefrologia. 2016. http://d
howed mildly decreased C3 (76.5 mg/dL, reference range:
0–180 mg/dL) and positive MPO-ANCA (28 IU/ml, reference
ange: negative <3.5, positive >5 IU/mL). Chest X-ray showedinﬁltrates in both lungs. Non-contrast computed tomography
of the chest showed interstitial reticular ﬁbrotic inﬁltra-
tion with honeycomb appearance of bilateral lungs and
consolidation in the left lung zone. Renal ultrasonography
demonstrated normal-sized kidneys with increased cortical
echogenicity. Ultrasound-guided renal biopsy was performed
and revealed a proliferative glomerulonephritis with scle-
rosis and crescentic formation (Fig. 1). Immunoﬂuorescent
microscopy of the glomeruli was negative for staining of IgA,
IgG, IgM, C1 and C3. Based on the above-mentioned examina-
tion results and clinical manifestations, severe MPO-ANCA (+)
RPGN with pulmonary-renal syndrome was diagnosed. During
the initial admission, emergent hemodialysis and plasma-
pheresis (5 sessions) were performed. Immunosuppressant
therapy including pulse steroids (methylprednisolone 500 mg
daily for 6 days) followed by oral prednisolone (5 mg  BID)
and azathioprine (50 mg  daily) and targeted therapy with ritu-
ximab (total 3 g over 3 divided fractions) were also added.
Nonetheless, high ANCA titers and poor renal function per-
sisted so immunosuppression therapy and hemodialysis were
maintained. Unfortunately, the patient died 1.5 years later
from septic shock due to community-acquired pneumonia.
IPF may be an insidious lesion of vasculitis or a separate
entity. It is now known that a subset of IPF patients are ANCA
positive.1 A recent study examined the differences between
ANCA positive and ANCA negative IPF. The levels of serum cre-
atinine and C-reactive protein in patients with positive ANCA
are signiﬁcantly higher than those with negative ANCA. The
survival rate of patients with higher titers of ANCA was less
than patients with lower levels, implying the concentration
of ANCA not only reﬂects the degree of systemic inﬂamma-
tion, but also indicates a more  unfavorable prognosis. Mostic pulmonary ﬁbrosis developed into ANCA-positive rapidly progres-
x.doi.org/10.1016/j.nefro.2016.09.005
ANCA (+) IPF is MPO-ANCA, which is related to the develop-
ment of crescentic glomerulonephritis in animal models7 and
could develop into RPGN clinically. In our literature search, we
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Table 1 – Clinical characteristics of patients with idiopathic pulmonary ﬁbrosis who developed into rapidly progressive glomerulonephritis.
Case(ref.) Age (y)/Sex Durationa (y) Initial symptoms SCrb
(mg/dL)
MPO-ANCA levels
(pre/post treatment)c
Seroconversion
of ANCA
Renal
histology
Treatmentd Renal outcome
Hiromura et al.2 48/F 1 Dyspnea, cough, fever 2.5 225, 15 (EU/ml) N/A Yes S, C Recovery
Hiromura et al.2 77/M 5 Shortness of breath 4.4 998,109 (EU/ml) N/A –  S, C Recovery
Hiromura et al.2 72/F 6 Fatigue, appetite loss 3.4 1379, decreased (EU/ml) N/A Yes S, C Improvede
Hiromura et al.2 70/M 4 Fatigue, fever 11.1 581, decreased (EU/ml) N/A –  S, C Hemodialysis
Chikaraishi et al.3 52/M 9 Claudication, paresthesia, hematuria 0.7 80, 33 (EU/ml) Yes Yes S, C Recovery
Matsuyama et al.4 72/M 10 Fatigue, abdominal pain, fever 1.3 869, N/A (EU/ml) N/A Yes S Recovery
Eschun et al.5 67/F 4 Shortness of breath 2.2 High titer, N/A N/A Yes S, C Recovery
Amir et al.6 69/F 0.8 Dyspnea 7.1 403, N/A (U/L) Yes Yes S, C, P Recovery
Pineton et al.4 71/F 3 Dyspnea 6.1 High titer, undetectable Yes Yes S, C, P, R Recovery
Presented case 37/M 12.5 Shortness of breath, edema 21.1 28, 29 (IU/ml) Yes Yes S, A, P, R Hemodialysis
ref.: reference, y: year, M: male, F: female, N/A: not applicable.
a Duration between the onset of IPF and RPGN.
b Serum creatinine level at RPGN diagnosed.
c MPO-ANCA levels before and after treatment during admission.
d S: steroids, C: cyclophosphamide, A: azathioprine, P: plasmapheresis, R: rituximab.
e The patient died during the treatment course due to respiratory failure.
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Fig. 1 – Imaging studies of the lungs and microscopic slides of renal tissue. (A) Chest X ray – Interstitial reticular ﬁbrotic
inﬁltration with honey comb appearance over both lungs. (B) Non-contrast computed tomography of the chest shows
pulmonary ﬁbrosis with cystic change in bilateral lung ﬁelds, with lower lung zones predominance. Inﬁltrates and
ground-glass opacity in bilateral peri-hilar regions were  also noted. (C) Renal biopsy (400×) – Glomeruli showed
mesoangiocapillary proliferation and segmental sclerosis. Fibro-cellular crescents are also seen.
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1ound 10 patients with acute ANCA (+) RPGN in IPF patients,
ll of whom had MPO-ANCA2–4,8–10 (Table 1). Seven out of
he 10 reported cases were Asians; however, the initial symp-
oms, time duration between IPF diagnosis and onset of RPGN,
erum levels of MPO-ANCA varied widely, indicating the clin-
cal manifestations of such cases are highly unpredictable.
ecent studies have revealed two major pathways to tissue
amage from ANCA associated vasculitis: the neutrophil path-
ay and the T-cell pathway. In the neutrophil pathway, an
nfection leads to the priming of neutrophils with an increase
f adhesion molecules and ANCA-binding antigens on their
urface. The binding of ANCA on neutrophils activates the
egranulation process and cause damage to the endothelial
ayer. Under the T-cell pathway, regulatory T cells take over
he function of tertiary lymphoid organs and promote further
mmune response. These two mechanisms interact with each
ther and magnify the cascade of inﬂammation and conse-
uently causing vasculitis.5
To the best of our knowledge, the present case was
he youngest and the longest interval between IPF and
PGN diagnoses in the reported literature. Despite ANCA-
egativity at IPF diagnosis 12.5 years ago, he subsequently
eveloped ANCA-positive RPGN; the trigger of this serocon-
ersion is unknown. The long duration might have been
ffected by the patient’s regular use of prednisolone and
olchicine, as colchicine may down-regulate multiple inﬂam-
atory responses and slow down the cascade of vasculitis.6
n conclusion, this case highlights the importance of regular
onitoring levels of ANCA and alertness for renal involvement
n patients with IPF.Please cite this article in press as: Yeung C-Y, et al. ANCA-negative idiopath
sive glomerulonephritis after 12 years follow up. Nefrologia. 2016. http://d
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